Cerebraca wafer not checked

Everfront Biotech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2/3 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Cerebraca Wafer, (75 mg (Z)-n-butylidenephthalide, (Z)-BP, Implant)”In the company’s words, NCT07349693 on ClinicalTrials.gov
Tested for
Recurrent Glioblastoma, IDH-Wildtype
Main trialPhase 2/3
“This study is designed as a multi-center, randomized, open-label trial to evaluate the efficacy of Cerebraca Wafer in patients with recurrent glioblastoma. Cerebraca Wafer is intended for use in recurrent glioblastoma as an adjunct to surgery (followed by standard-of-care temozolomide), demonstrating potential to improve outcomes in this serious and life-threatening condition”In the company’s words, NCT07349693 on ClinicalTrials.gov

Other drugs for Recurrent Glioblastoma, IDH-Wildtype

All 93 drugs for Recurrent Glioblastoma, IDH-Wildtype

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2/3Not yet recruiting 30 Mar 2029 Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma
Phase 1/2Completed 30 Apr 2023 A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cerebraca wafer

Following is part of Solo: you see every change to Cerebraca wafer the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in